Back to discover

Protein / target

Somatoliberin

Encoded byGHRHP01286Homo sapiensSwiss-Prot
UniProt: P01286Ensembl: ENSG00000118702HGNC: HGNC:4265NCBI Gene: 2691
Small-molecule tractable
Druggability
Structure with Ligand
1
Research papers

Protein at a glance

Biological role

Growth hormone-releasing hormone receptor binding

Strongest disease association

Neoplasms

Via encoding gene GHRH · Literature evidence · score 0.10

Research activity

Emerging research

1 papers · latest 2023

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

GRF is released by the hypothalamus and acts on the adenohypophyse to stimulate the secretion of growth hormone

Subcellular location

Secreted
Domains and Gene Ontology detail (21)

Gene Ontology

  • Cextracellular region
  • Cextracellular space
  • Cperikaryon
  • Cterminal bouton
  • Fgrowth hormone-releasing hormone activity
  • Fgrowth hormone-releasing hormone receptor binding
  • Fneuropeptide hormone activity
  • Fpeptide hormone receptor binding
  • Padenohypophysis development
  • Padenylate cyclase-activating G protein-coupled receptor signaling pathway
  • Pcell-cell signaling
  • Pgrowth hormone secretion

108 aa · 12 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Growth-factor signallingGOCell proliferation & survivalGO
View supporting evidence

Growth-factor signalling

  • ·positive regulation of insulin-like growth factor receptor signaling pathway

Cell proliferation & survival

  • ·positive regulation of cell population proliferation

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene GHRH

Gene-level evidence surfaced through the gene GHRHthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Neoplasms
0.12Preliminary

Literature evidence dominant · Open Targets 0.10 · no direct causal or clinical evidence

Endometrial Neoplasms
0.10Preliminary

Literature evidence dominant · Open Targets 0.08 · no direct causal or clinical evidence

Benign prostatic hyperplasia
0.08Preliminary

Literature evidence dominant · Open Targets 0.07 · no direct causal or clinical evidence

Acromegaly
0.08Preliminary

Literature evidence dominant · Open Targets 0.07 · no direct causal or clinical evidence

Lung carcinoma
0.08Preliminary

Literature evidence dominant · Open Targets 0.06 · no direct causal or clinical evidence

View evidence synthesis (5)
NeoplasmsPreliminary
0.12
agreement 0.00–0.39
Literature100%

Open Targets aggregate 0.10 · 1 independent evidence family · no direct causal or clinical evidence

Endometrial NeoplasmsPreliminary
0.10
agreement 0.00–0.37
Literature100%

Open Targets aggregate 0.08 · 1 independent evidence family · no direct causal or clinical evidence

Benign prostatic hyperplasiaPreliminary
0.08
agreement 0.00–0.36
Literature100%

Open Targets aggregate 0.07 · 1 independent evidence family · no direct causal or clinical evidence

AcromegalyPreliminary
0.08
agreement 0.00–0.35
Literature100%

Open Targets aggregate 0.07 · 1 independent evidence family · no direct causal or clinical evidence

Lung carcinomaPreliminary
0.08
agreement 0.00–0.35
Literature100%

Open Targets aggregate 0.06 · 1 independent evidence family · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Neoplasms0.10
Endometrial Neoplasms0.08
Benign prostatic hyperplasia0.07
Acromegaly0.07
Lung carcinoma0.06
Lung Neoplasms0.06

Tractability

Small molecules — Emerging

Feasibility evidence (structure with ligand) — no clinical-stage drug of this modality recorded.

Antibodies — Emerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (4)
SM · Structure with LigandAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMM

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2023

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Growth hormone-releasing hormone antagonist MIA-602 inhibits inflammation induced by SARS-CoV-2 spike protein and bacterial lipopolysaccharide synergism in macrophages and human peripheral blood mononuclear cells.15 cites

Granato G · Frontiers in immunology · 2023

Recent

Growth hormone-releasing hormone antagonist MIA-602 inhibits inflammation induced by SARS-CoV-2 spike protein and bacterial lipopolysaccharide synergism in macrophages and human peripheral blood mononuclear cells.

Granato G · Frontiers in immunology · 2023

Europe PMC papers linked directly to this protein.